SEPT9 methylation analysis for CRC detection in plasma is now available as an FDA-approved commercial test (Epi ProColon 2.0, Epigenomics AG Coporation, Berlin, Germany). This evidence concerns the gene SEPTIN9 and colorectal carcinoma.